Petros Pharmaceuticals Inc SEC Filings

PTPI OTC

Welcome to our dedicated page for Petros Pharmaceuticals SEC filings (Ticker: PTPI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

Petros Pharmaceuticals’ push to move its flagship erectile dysfunction therapy from prescription to over-the-counter status makes each SEC disclosure dense with FDA milestones, R&D outlays, and device-segment margins. Finding where the company details Additional Conditions for Nonprescription Use or breaks down vacuum erection system revenue inside a 300-page document can slow even seasoned analysts.

Stock Titan’s platform turns that obstacle into clarity. Our AI-powered summaries translate the legal language of every Petros Pharmaceuticals annual report 10-K simplified, pinpoint the latest Petros Pharmaceuticals quarterly earnings report 10-Q filing, and surface Petros Pharmaceuticals 8-K material events explained within minutes of hitting EDGAR. Need to follow Petros Pharmaceuticals Form 4 insider transactions real-time? We stream alerts on executive stock transactions as they occur, then overlay context so you understand whether insiders are buying ahead of pivotal FDA meetings. The same engine answers natural questions like “understanding Petros Pharmaceuticals SEC documents with AI” or “Petros Pharmaceuticals proxy statement executive compensation” directly on the page.

Whether you’re comparing clinical trial spending quarter-over-quarter, gauging market reception to a potential Rx-to-OTC switch, or monitoring Petros Pharmaceuticals insider trading Form 4 transactions for sentiment cues, every filing type is organized and annotated. You’ll get Petros Pharmaceuticals earnings report filing analysis, governance insights, and risk-factor highlights without wading through jargon. Real-time updates, comprehensive coverage, and expert commentary give you the confidence to act on what matters most.

06/20/2025 05:20 PM

Filing

[8-K] PETROS PHARM INC Reports Material Event

Rhea-AI Summary

Form 4 Overview: Maravai LifeSciences Holdings, Inc. (MRVI) disclosed that director John A. DeFord acquired 89,139 shares of Class A common stock on 16 June 2025.

Transaction details: The shares were granted as restricted stock units (RSUs) under the company’s 2020 Omnibus Incentive Plan at an assigned value of $2.16 per share. These RSUs will vest in full on the earlier of (i) one year from the grant date or (ii) the date of the 2026 annual shareholder meeting.

Post-transaction ownership: Following the award, DeFord’s beneficial ownership rises to 159,185 shares, all held directly.

Implications: A director increasing his stake—albeit via equity compensation—tends to align management and shareholder interests and can be interpreted as a vote of confidence in MRVI’s long-term prospects. Because the grant stems from an incentive plan rather than an open-market purchase, any cash outlay by the insider is not indicated in the filing.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

FAQ

What is the current stock price of Petros Pharmaceuticals (PTPI)?

The current stock price of Petros Pharmaceuticals (PTPI) is $0.0349 as of July 3, 2025.

What is the market cap of Petros Pharmaceuticals (PTPI)?

The market cap of Petros Pharmaceuticals (PTPI) is approximately 342.5K.

What is the core business of Petros Pharmaceuticals Inc?

Petros Pharmaceuticals focuses on men’s health, developing innovative therapies for erectile dysfunction and other related conditions through both prescription medications and medical devices.

How does Petros generate revenue?

The company generates revenue primarily through its Medical Devices segment and also through its Prescription Medications segment, which includes the distribution of therapies like vacuum erection devices both domestically and internationally.

What technological innovations is Petros Pharmaceuticals integrating?

Petros is integrating a proprietary web application with AI-driven diagnostic tools to improve consumer self-selection for treatment, thereby supporting the potential transition of its flagship therapy from a prescription to an OTC product.

What makes Petros' approach to men's health unique?

The company’s unique approach lies in its focus on both innovative product development and technological integration. Its collaboration with experts and utilization of advanced digital platforms for patient screening set it apart in the men's health sector.

How is Petros preparing for an Rx-to-OTC switch?

Petros is conducting rigorous studies and developing technology platforms that comply with FDA guidelines, including Additional Conditions for Nonprescription Use (ACNU). This methodical approach is designed to facilitate a safe transition from Rx to OTC status.

What role does digital technology play in Petros' market strategy?

Digital technology plays a pivotal role in Petros’ strategy by enhancing consumer guidance and self-selection through a specialized web application. This technology not only improves product safety but also empowers consumers to make informed treatment decisions.

Who are the key collaborators for Petros Pharmaceuticals?

Petros collaborates with leading researchers, clinical experts, regulatory advisors, and telemedicine providers. This multidisciplinary approach ensures that its products meet rigorous scientific, clinical, and regulatory standards.

What market segment does Petros target with its innovations?

The company targets the burgeoning self-care and men’s health market, aiming to expand access to prescription-grade therapies through OTC solutions and technology-driven healthcare platforms.